Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383533
Status:
RECRUITING
Last Update Posted:
2024-04-26
First Post:
2024-04-22
Brief Title:
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Organization Data
Organization:
Zhejiang Cancer Hospital
Class:
OTHER
Study ID:
IRB-2023-385
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Zhejiang Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Ying Jieer
Responsible Party Title:
Chief physician
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Zhejiang Cancer Hospital
Old Name:
None
Old Organization:
None